This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CARLSBAD, Calif., Nov. 24, 2010 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that its Chairman and CEO, Christopher Gleeson, will be presenting an update on the company's progress at the Piper Jaffray 22
nd Annual Health Care Conference held at the New York Palace hotel on Tuesday, November 30, 2010 at 10:30 am eastern time. The update will be concurrently webcast and can be accessed via the company's website under the Investor Relations webpage.
GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark's XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed five diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.